Back

Xanthine oxidase inhibitors in cardiovascular disease: impact on mortality and ATP dynamics

29 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Basic concepts in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Masanari Kuwabara

Jichi Medical University, Shimotsuke (Japan)

5 More presentations in this session

Presentation thumbnail
Effect of qiliqiangxin according to N-terminal pro-B-type natriuretic peptide in patients with heart failure and reduced ejection fraction: insights from QUEST
Doctor L. Shen (Glasgow, CN)
Abstract Slides Video
Presentation thumbnail
Feasibility of a novel implantable device to provide heart failure therapy and left atrial pressure monitoring in a chronic animal study
Doctor S. Ge (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Beneficial effects of treatment with a soluble guanylate cyclase stimulator on cardiac function and mitochondrial activity in an animal model of early-stage HFpEF
Mr X. Vazquez-Abuin (Santiago De Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Amyloid-beta metabolism, cardiac remodeling and myocardial recovery in advanced heart failure
Doctor G. Zervas (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Myeloid-specific Nrf2 deletion increases fibrosis and contributes to the development of heart failure after murine myocardial infarction
Miss T. Ali (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Basic concepts in heart failure

The Event

Event poster

ESC Congress 2025

29 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Xanthine oxidase inhibitors withdrawal syndrome
thumbnail
Congress Presentation
Comparative clinical outcomes on renal function and mortality of uricosuric agents versus xanthine oxidase inhibitors in patients with hyperuricemia and cardiovascular risks
thumbnail
Congress Presentation
Xanthosine alleviates myocardial ischemia-reperfusion injury through attenuation of cardiomyocyte ferroptosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources